Welcome to our dedicated page for Aemetis SEC filings (Ticker: AMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Carbon-credit revenues, dairy digester build-outs and dual-continent operations make Aemetis Inc. (AMTX) filings anything but straightforward. If you have ever combed through a 300-page annual report hunting for Low Carbon Fuel Standard revenue or segment data from the company’s Indian biodiesel plant, you know the challenge.
Stock Titan removes that friction. Our AI-powered summaries turn dense 10-K text into plain-language insights, while real-time alerts flag each new Aemetis quarterly earnings report 10-Q filing and every Aemetis 8-K material events explained. Want instant visibility into Aemetis insider trading Form 4 transactions? We surface Form 4 details the moment they hit EDGAR, linking trades to upcoming credit milestones so you can monitor Aemetis executive stock transactions Form 4 in context.
Explore every document type in one place:
- 10-K: Cash-flow swings and LCFS credit economics—Aemetis annual report 10-K simplified.
- 10-Q: Quarterly production yields and RNG pipeline spend—Aemetis earnings report filing analysis.
- 8-K: Plant outages, new offtake agreements, tax-credit sales.
- DEF 14A: Aemetis proxy statement executive compensation with AI comparisons to peer renewables.
- Form 4: Aemetis Form 4 insider transactions real-time alerts.
Use cases professionals rely on: compare segment margins quarter-over-quarter, trace capital expenditures on biogas digesters, and verify carbon-intensity assumptions—understanding Aemetis SEC documents with AI saves hours and sharpens decisions. From the first dairy RNG project note to the latest share-sale disclosure, every AMTX filing is here, explained simply.
Aemetis, Inc. filed its Q3 2025 10‑Q, reporting revenue of $59.2 million for the quarter and a net loss of $23.7 million. For the nine months, revenue was $154.3 million with a net loss of $71.7 million.
Quarterly results reflected softer biodiesel sales in India and a near break‑even gross margin, while SG&A was $8.5 million. Interest and financing costs remained heavy, with quarterly interest expense of $11.9 million and total other debt‑related costs of $3.3 million.
As of September 30, 2025, cash and equivalents were $5.6 million ($8.6 million including restricted), total debt was $353.5 million, and the ABGL Series A preferred units liability was $131.0 million. The company recorded $16.4 million net cash provided by financing year‑to‑date and $(2.5) million net cash used in operations. Shares outstanding were 65.0 million as of September 30, 2025, and 65,568,542 as of October 31, 2025.
ABGL’s Series A preferred redemption deadline was extended to December 31, 2025; if not redeemed, a credit agreement effective January 1, 2026 would replace it at an interest rate equal to the greater of prime + 10.0% or 16.0%.
Aemetis (AMTX) reported that it issued an earnings press release for the three and nine months ended September 30, 2025. The release is furnished as Exhibit 99.1 to a Form 8-K under Item 2.02 and Item 7.01, and is posted on the company’s website. The Form 8-K and Exhibit 99.1 are deemed “furnished” rather than “filed” under the Exchange Act and are not incorporated by reference into any registration statement.
Aemetis, Inc. disclosed that subsidiary Aemetis Biogas LLC (ABGL) executed a Tenth Waiver and Amendment to its Series A Preferred Unit Purchase Agreement with Protair-X Technologies Inc. and Third Eye Capital, effective August 31, 2025. The amendment extends ABGL’s deadline to redeem all outstanding Series A Preferred Units from August 31, 2025 to December 31, 2025 and sets the aggregate redemption price at $118.8 million, which includes a $2 million amendment fee.
If ABGL does not redeem by the new deadline, it will enter a Credit Agreement in substantially the attached form, effective January 1, 2026, maturing September 1, 2026, with interest at the greater of 16.0% or the prime rate plus 10.0%. The agreement would require guarantees from Aemetis, Inc. and certain subsidiaries and grant security interests in the assets of ABGL and the guarantors. Protair-X currently owns 100% of ABGL’s Series A Preferred Units.
Barton Francis P, identified as a director of Aemetis, Inc. (AMTX), reported multiple open-market sales of the issuer's common stock on 08/14/2025. Four sale transactions at a price of $2.5335 per share disposed of 1,300, 12,152, 5,000 and 8,000 shares, totaling 26,452 shares sold. The filings show the reporting person’s beneficial ownership decreased from 233,670 shares pre-sale (as reflected after the first line) to 208,518 shares following the last reported transaction. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
A Form 144 notice shows a proposed sale of 26,452 shares of common stock of the issuer via Raymond James & Associates on 08/14/2025, with an aggregate market value of $66,923.56. The shares reported for sale were granted as restricted stock units (RSUs) by the issuer on 01/07/2021 (1,300 shares), 04/08/2021 (12,152 shares), 11/18/2021 (5,000 shares), and 08/18/2022 (8,000 shares). The filer reports no securities sold during the past 3 months and indicates payment for these proposed sales will be cash. The filing includes the standard representation that the seller does not possess undisclosed material information about the issuer.
FAQ
What is the current stock price of Aemetis (AMTX)?
What is the market cap of Aemetis (AMTX)?
